Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury
Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton
Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton
View: Text | PDF
Research Article Immunology Inflammation

Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury

  • Text
  • PDF
Abstract

Identifying host factors that contribute to pneumonia incidence and severity are of utmost importance to guiding the development of more effective therapies. Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1, encoded by OLR1) is a scavenger receptor known to promote vascular injury and inflammation, but whether and how LOX-1 functions in the lung are unknown. Here, we provide evidence of substantial accumulation of LOX-1 in the lungs of patients with acute respiratory distress syndrome and in mice with pneumonia. Unlike previously described injurious contributions of LOX-1, we found that LOX-1 is uniquely protective in the pulmonary airspaces, limiting proteinaceous edema and inflammation. We also identified alveolar macrophages and recruited neutrophils as 2 prominent sites of LOX-1 expression in the lungs, whereby macrophages are capable of further induction during pneumonia and neutrophils exhibit a rapid, but heterogenous, elevation of LOX-1 in the infected lung. Blockade of LOX-1 led to dysregulated immune signaling in alveolar macrophages, marked by alterations in activation markers and a concomitant elevation of inflammatory gene networks. However, bone marrow chimeras also suggested a prominent role for neutrophils in LOX-1–mediated lung protection, further supported by LOX-1+ neutrophils exhibiting transcriptional changes consistent with reparative processes. Taken together, this work establishes LOX-1 as a tissue-protective factor in the lungs during pneumonia, possibly mediated by its influence on immune signaling in alveolar macrophages and LOX-1+ airspace neutrophils.

Authors

Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, Theodore J. Standiford, Jawahar L. Mehta, Tatsuya Sawamura, Matthew R. Jones, Joseph P. Mizgerd, Katrina E. Traber, Lee J. Quinton

×

Figure 2

Local inhibition of LOX-1 exacerbates lung injury and inflammation during pneumonia.

Options: View larger image (or click on image) Download as PowerPoint
Local inhibition of LOX-1 exacerbates lung injury and inflammation durin...
Age-matched C57BL/6 mice were intratracheally treated with 10 μg anti–LOX-1 or control IgG and E. coli (n = 5–13 per group depending on experimental outcome). (A) Neutralization of LOX-1 was confirmed by measuring BALF sLOX-1 at 24 hours after anti–LOX-1 or IgG treatment and infection with E. coli. (B) Total protein was measured in BALF at the indicated time points as an index of alveolar edema. (C) H&E staining was performed on paraffin-embedded lung sections collected from anti–LOX-1– and IgG-treated mice at 24 hours postinfection. Original magnification, ×40. Arrows point to examples of elevated injury, with visual evidence of proteinaceous edema and fibrin deposition. (D) Lactate dehydrogenase (LDH) levels were measured in BALF collected from mice with or without infection in the presence of anti–LOX-1 or IgG treatment. (E) Cytokine concentrations were measured in BALF at 24 hours postinfection. (F) Flow cytometry was performed on collagenase-digested lungs collected from anti–LOX-1– and IgG-treated mice infected with E. coli for 24 hours and intravenously treated with a fluorescently labeled anti-CD45.2 Ab 3 minutes prior to euthanasia to determine extravascular neutrophil (i.v. CD45–CD45+CD11b+Ly6G+), inflammatory monocyte (i.v. CD45–CD45+CD11b+Ly6Chi), and alveolar macrophage (i.v. CD45–CD45+CD11c+SiglecF+) numbers. (G) Survival was determined through 48 hours. Data are represented as mean ± SEM with individual data points representative of mice from 2–3 independent experiments. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 for 2-tailed Welch’s t test (A), Mann-Whitney test (B [12 hours], D [G-CSF]), 2-tailed, unpaired t test (B [24 hours], C and D [except G-CSF], F), or log-rank (Mantel-Cox) test (G). EV, extravascular.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts